Firebird Management's Steve Gorelik's Molina Healthcare Bull Thesis $MOH
Summary
Steve Gorelik’s Molina Healthcare ($MOH) thesis is a bet on the lowest-cost operator surviving a Medicaid industry downturn and emerging with more share. Molina manages coverage for roughly 5 million people, generates about $40 billion of annual revenue, and has historically grown revenue 10–15% a year. Its specialization and roughly 7% administrative-cost ratio make it, in Gorelik’s words, “the Walmart” of Medicaid managed care.
The stock’s roughly 50% collapse reflects a genuine margin shock, not merely bad sentiment. Industry medical costs have risen from a normal 85–90% of premiums to roughly 92%; Molina’s margin has consequently fallen from about 4% to 2%, while peers such as Centene are reportedly losing money at a roughly 94% medical-cost ratio. The recovery depends on state premium increases catching up with utilization: “If medical costs continue to go up faster than the premium, the rest of industry will be losing money while Molina will still be profitable.”
Post-COVID Medicaid redeterminations exposed a forecasting error that could recur under the One Big Beautiful Bill Act. Roughly 8% of Medicaid beneficiaries lost coverage after emergency protections ended, but those removed were disproportionately younger and healthier, leaving a more expensive risk pool; Gorelik says insurers, possibly including Molina, underestimated this selection effect. The new budget could remove another approximately 10 million people from an 80 million-person market, potentially extending depressed profitability if healthier members again leave first.
Walker’s strongest pushback is that a policy-dependent insurer earning 25–50% on equity could invite reimbursement pressure or harsher regulation. Gorelik’s answer is that states generally pay winning plans the same per-member rate, so Molina’s excess return comes from operating at roughly 7% administrative cost where competitors spend 10% or more—not from receiving richer reimbursement. States also need MCOs because recreating provider networks, billing infrastructure, and care management themselves would be difficult to do more cheaply than the industry’s normal 2–4% margins.
The thesis retains both organic and acquisition-driven growth despite Medicaid enrollment pressure. Molina lost roughly 2–3% of members while the broader market lost about 8%, wins approximately 80% of the tenders it chooses to participate in, and has been adding around 0.2 percentage points of market share annually—about 160,000 members on an 80 million-person base. Management has said roughly two-thirds of its targeted growth through 2027 is already secured through awarded tenders and completed acquisitions.
Molina’s repeatable M&A playbook turns unprofitable local plans into potentially high-return bolt-ons. Over five years it spent about $2.6 billion to acquire roughly 1.2 million members and $9–10 billion of revenue, then applied the “Molina playbook” to reduce acquired administrative-cost ratios from 10–12% toward its own level. Gorelik estimates the purchase price at roughly 12 times earnings on today’s margin or four times at a normalized margin.
The cleanest thesis-break is a prolonged period in which medical costs outrun state rates, but Gorelik prefers Molina precisely because it can endure that scenario longer than peers. He would be comfortable owning it if the market closed for five years. The next capital-allocation signal is whether buybacks resume after a $500 million first-quarter repurchase and a second-quarter pause: continued buying would suggest management believes the cost deterioration is containable.
Deep dive
1. Molina is the Medicaid specialist inside a thin-margin system
Gorelik describes Molina Healthcare as a managed-care organization that primarily administers state Medicaid programs. States determine eligibility, tender contracts, and typically divide members among four or five winning insurers; Molina then assembles the hospitals, doctors, and other providers required to deliver care for a fixed per-member payment.
The scale is substantial despite Molina’s relatively small share: approximately $10 billion of market capitalization, about $40 billion of annual revenue, and roughly 5 million covered people—about 6% of Americans enrolled in Medicaid. Gorelik places it around third or fourth in Medicaid managed care, behind larger operators such as Centene and UnitedHealthcare.
Growth has historically run at roughly 10–15% annually through two channels: winning more than its fair share of state tenders and buying underperforming insurers. The acquisitions matter because Molina is not merely adding membership; it is acquiring inefficient cost structures that management believes it knows how to repair.
2. The stock halved because a two-point cost miss can erase the economics
Walker frames the setup starkly: a two-decade “up and to the right” compounder began the year near $300, peaked around $350, and then fell from roughly $300 to $150 between July and late August, trading around $185 as they spoke. The question is whether that collapse created a cheap compounder or revealed a structurally impaired business.
Medicaid plans are capitated, but not free to maximize underwriting profit. For every $1,000 received, an insurer normally spends $850–$900 on care; if Medicaid medical spending drops below 85%, it may owe the state a refund, as happened when COVID suppressed procedures. The remaining 10–15% must cover administration before shareholders earn anything.
The current problem is the reverse: industry medical costs have climbed to roughly 92% of premiums, while administrative expenses consume another 9–10%, making the sector collectively unprofitable. Molina’s medical-cost ratio was about 90.5% in 2024, but its normal 4% margin has still fallen to about 2%—“their profitability has halved just like the stock price did.”
Walker’s concern is that management already called rising costs temporary at its November 2024 investor day, only for pressure to worsen into the following second quarter. Gorelik concedes the miss: medical costs rose faster than both insurers and analysts expected, and the market is rationally skeptical that promised rate increases will fully close the gap.
3. Molina’s moat is an operating culture, not superior scale
Gorelik’s central differentiation is administrative efficiency. Competitors might spend roughly the same 90% on medical care, but a large operator such as UnitedHealthcare can consume the remaining 10% in administration; Molina spends closer to 7%, leaving a profit even during an industry downturn.
Walker challenges the apparent anomaly: why should perhaps the seventh-largest insurer operate more efficiently than companies possessing greater scale and technology budgets? Gorelik’s answer is focus—Molina predominantly does Medicaid, while diversified insurers can tolerate higher overhead because commercial insurance has lower medical costs. Specialization makes cost discipline “in their DNA.”
The turning point came in 2017, when Joseph Zubretsky joined from outside—Gorelik believes he had been at Aetna—and the company moved away from the founder’s two-sons regime, which Gorelik calls “a glorified nonprofit.” The new team installed the “Molina playbook,” which Gorelik compares with the Danaher system: relentless, repeatable attention to cost and execution while continuing to grow.
Walker accepts that culture is both difficult to prove in a spreadsheet and powerful when genuine: it appears indirectly through margins, returns, and years of results. Gorelik’s chosen analogy is a focused low-cost operator—“the Walmart of retail”—providing the essential product without carrying the overhead of full-service competitors.
4. Redeterminations changed the risk pool, and another round may delay recovery
After the COVID medical emergency ended, states resumed Medicaid eligibility redeterminations. During the emergency, beneficiaries could not lose coverage even if their income or circumstances improved; once that protection disappeared, roughly 8% of enrollees rolled off.
The surprise was not simply fewer members but adverse selection. Those leaving were disproportionately younger, healthier, newly employed, or otherwise less reliant on care, while the remaining population required more medical spending. Gorelik says insurers, possibly including Molina, failed to estimate this effect correctly.
Utilization also shifted in ways Molina underestimated, particularly higher behavioral-health use—possibly because the stigma around seeking care diminished. Traditional inflation added pressure through drug prices and higher compensation for physicians and nurses, while the key question is whether premiums, which historically increased around 4–5% annually, will keep pace with medical costs.
The proposed remedy is repricing. Centene, whose Medicaid medical-cost ratio Gorelik puts near 94%, has discussed rate increases of 10% or more to restore profitability; Molina also expects states to raise rates. Yet the thesis remains conditional: recovery arrives only if premium increases meet or exceed the medical-cost trend.
5. Policy can shrink enrollment, but Molina may keep gaining share
The One Big Beautiful Bill Act could reduce Medicaid enrollment by around 10 million people from a base near 80 million—roughly 10–12%. Walker asks whether Molina’s Medicaid membership, already down from about 4.9 million to below 4.8 million, could fall toward 4.6 million over the next 18 months.
Gorelik’s rebuttal is relative: Molina lost only 2–3% of members while the industry lost roughly 8%, so it gained share through the dislocation. It wins about 80% of the tenders it elects to pursue, and its approximately 0.2-point annual share gain represents around 160,000 members on the national base.
Management’s mid-single-digit revenue growth outlook through 2027 is not entirely prospective. Gorelik says roughly two-thirds of the expected growth is already secured through awarded tenders not yet implemented and completed acquisitions, providing a backlog even if the total Medicaid population contracts.
Walker’s broader tail-risk question remains: two presidential elections and multiple congressional cycles make a ten-year Medicaid forecast inherently political. Gorelik does not dismiss “irrational policy,” but argues that eliminating coverage for tens of millions of voting citizens would require an alternative system—and states are unlikely to recreate MCO infrastructure more cheaply.
6. Denials are the uncomfortable mechanism behind lower system costs
Walker presses on public anger toward health insurers: if plans are paid a fixed amount, the incentive appears to be “deny, deny, deny” until spending fits the cap. Gorelik draws a necessary distinction between denying payment after a procedure has occurred and refusing authorization before a procedure takes place; the former can leave privately insured patients with devastating bills.
Molina has attracted reports that it denies procedures more often than peers, which might help manage medical costs. Gorelik does not claim every decision is right—“there’s going to be situations where the insurers will make a mistake”—but argues that anecdotes must be weighed against extensive overtreatment in the American system.
His system-level example is that Americans make fewer physician visits than residents of comparable countries yet receive more interventions per visit, including roughly 50% more MRIs and, by the statistic he cites, about 50% more stents in certain cardiac cases. The country spends roughly $17,000 per person and 17% of GDP on healthcare without achieving better outcomes.
Walker tests the implication directly: is Medicaid paying correctly while private insurance pays too richly? Gorelik says that is fair. Providers have told him they lose money on Medicare, break even on Medicaid, and earn their profit on commercial patients; Molina typically has about two years to assemble the provider network required before it can tender, and its presence in some states lets it reuse networks in additional tenders.
7. Bolt-on M&A and aligned capital allocation support the long-duration case
Despite industry consolidation, Gorelik says the top five Medicaid operators—Centene, UnitedHealthcare, Wellpoint, Humana, and Molina—control only around half the market. The remainder includes state-level plans covering perhaps 50,000–200,000 members, often with revenue and members but 10–12% administrative-cost ratios and no profits.
Molina spent about $2.6 billion over five years acquiring roughly 1.2 million members and $9–10 billion of revenue. By applying its playbook over two to three years, it seeks to pull acquired overhead toward 7%; Gorelik calculates that Molina paid roughly 12 times earnings at today’s depressed margin or around four times normalized earnings.
Leadership alignment adds weight. The CEO owns about 400,000 shares, worth roughly $80–90 million at the discussed price, and can receive another 150,000 shares by remaining through 2027 and reaching $36 of EPS. Walker’s reading is blunt: the potential award could be worth $30–60 million, enough to make the target personally meaningful.
Buybacks are the near-term tell. Molina repurchased about $500 million in the first quarter, then did little in the second as medical-cost ratios deteriorated; Gorelik calls that pause sensible. Whether purchases resume in the third quarter will indicate how comfortable management is with the cost deterioration.
Walker closes with the “Scooby-Dooing” framework, from a post by Gorelik’s partner Harvey Sawikin: management deliberately depressing its stock to repurchase cheaply. Gorelik says analysts should distinguish that from a stock falling because management is poor; he points to Molina’s track record of delivering results and gives no indication that such deliberate stock-price suppression is occurring here.